Get the Stockscreener App
7.96
11.33%
0.81
After Hours:
7.88
-0.08
-1.01%
Gyre Therapeutics Inc stock is traded at $7.96, with a volume of 330.87K.
It is up +11.33% in the last 24 hours and down -2.57% over the past month.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
See More
Previous Close:
$7.15
Open:
$7.75
24h Volume:
330.87K
Relative Volume:
3.66
Market Cap:
$766.65M
Revenue:
$106.66M
Net Income/Loss:
$15.16M
P/E Ratio:
85.13
EPS:
0.0935
Net Cash Flow:
$6.37M
1W Performance:
+7.42%
1M Performance:
-2.57%
6M Performance:
+9.19%
1Y Performance:
-35.70%
1-Day Range:
$7.75
$8.50
1-Week Range:
$7.15
$8.50
52-Week Range:
$6.11
$19.00
Gyre Therapeutics Inc Stock (GYRE) Company Profile
Name
Gyre Therapeutics Inc
Sector
Industry
Phone
(619) 949-3681
Address
12770 HIGH BLUFF DRIVE, SUITE 150, SAN DIEGO
Compare GYRE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GYRE
Gyre Therapeutics Inc
|
7.96 | 649.41M | 106.66M | 15.16M | 6.37M | 0.0935 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Gyre Therapeutics Inc Stock (GYRE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-26-25 | Initiated | H.C. Wainwright | Buy |
| Mar-11-25 | Initiated | Noble Capital Markets | Outperform |
| Apr-29-21 | Resumed | Stephens | Overweight |
| Feb-10-21 | Initiated | Piper Sandler | Overweight |
| May-21-20 | Initiated | Raymond James | Outperform |
| Jan-04-19 | Initiated | Oppenheimer | Outperform |
| Feb-12-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Feb-09-18 | Reiterated | Chardan Capital Markets | Buy |
| Dec-08-17 | Initiated | B. Riley FBR, Inc. | Buy |
| Jun-12-17 | Initiated | Chardan Capital Markets | Buy |
| Jun-06-17 | Initiated | Ladenburg Thalmann | Buy |
| Jun-30-16 | Initiated | Rodman & Renshaw | Buy |
View All
Gyre Therapeutics Inc Stock (GYRE) Latest News
Visual trend scoring systems applied to Gyre Therapeutics Inc.2025 Valuation Update & Risk Controlled Stock Pick Alerts - newser.com
This Aptiv Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Jefferies initiates Gyre Therapeutics stock with Buy rating, $16 target - Investing.com
Jefferies initiates Gyre Therapeutics stock with Buy rating, $16 target By Investing.com - Investing.com UK
Gyre Therapeutics (NASDAQ:GYRE) Earns Sell (D) Rating from Weiss Ratings - MarketBeat
Gyre Therapeutics Inc Stock Analysis and ForecastCandlestick Pattern Analysis & Small Investment Portfolio - earlytimes.in
Can momentum traders help lift Gyre Therapeutics Inc.Weekly Trend Report & Safe Entry Point Identification - newser.com
Gyre Therapeutics Inc. stock outlook for YEARJuly 2025 Big Picture & Low Drawdown Investment Ideas - newser.com
Volatility clustering patterns for Gyre Therapeutics Inc.Portfolio Value Summary & Short-Term Swing Trade Alerts - newser.com
Real time alert setup for Gyre Therapeutics Inc. performanceTrade Risk Report & Free Expert Approved Momentum Trade Ideas - newser.com
Gyre Therapeutics president Ma Songjiang sells $42,760 in stock - MSN
Discovering 3 Undiscovered Gems In The US Market - simplywall.st
Goldman Sachs Group Inc. Cuts Stock Position in Gyre Therapeutics, Inc. $GYRE - Defense World
Developing predictive dashboards with Gyre Therapeutics Inc. dataPortfolio Performance Report & AI Forecast Swing Trade Picks - newser.com
What analysts say about Gyre Therapeutics Inc stockStock Valuation Metrics & Free Quantitative Trading Strategies - earlytimes.in
Gyre Therapeutics president sells $45,380 in stock - MSN
Is Gyre Therapeutics Inc a good long term investmentEarnings Forecast Updates & Free Dynamic Capital Growth - earlytimes.in
Financial Survey: Theratechnologies (NASDAQ:THTX) vs. Gyre Therapeutics (NASDAQ:GYRE) - Defense World
Does Gyre Therapeutics Inc. qualify in momentum factor screeningJuly 2025 Fed Impact & Stock Portfolio Risk Management - newser.com
Gyre Therapeutics, Inc.(NasdaqCM: GYRE) added to S&P Global BMI Index - MarketScreener
Growth Review: Is Gyre Therapeutics Inc stock a value trapJobs Report & Short-Term High Return Ideas - خودرو بانک
Is Gyre Therapeutics Inc currently under institutional pressure2025 AllTime Highs & Risk Controlled Stock Pick Alerts - خودرو بانک
US Market Wrap: Will Gyre Therapeutics Inc stock hit new highs in YEARJuly 2025 Sentiment & Fast Entry High Yield Stock Tips - خودرو بانک
Aug Final Week: Is Gyre Therapeutics Inc stock showing strong momentumTrade Exit Summary & Community Consensus Stock Picks - خودرو بانک
Gyre Therapeutics Inc Stock (GYRE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Gyre Therapeutics Inc Stock (GYRE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ma Songjiang | President |
May 28 '25 |
Sale |
10.07 |
558 |
5,619 |
2,806,084 |
| Ma Songjiang | President |
May 22 '25 |
Sale |
10.97 |
2,000 |
21,940 |
2,808,824 |
| Ma Songjiang | President |
May 23 '25 |
Sale |
10.24 |
182 |
1,864 |
2,808,642 |
| Ma Songjiang | President |
May 20 '25 |
Sale |
11.25 |
2,000 |
22,500 |
2,812,824 |
| Ma Songjiang | President |
May 21 '25 |
Sale |
10.83 |
2,000 |
21,660 |
2,810,824 |
| Ma Songjiang | President |
May 16 '25 |
Sale |
11.31 |
2,000 |
22,620 |
2,816,824 |
| Ma Songjiang | President |
May 19 '25 |
Sale |
11.11 |
2,000 |
22,220 |
2,814,824 |
| Ma Songjiang | President |
May 15 '25 |
Sale |
10.68 |
2,000 |
21,360 |
2,818,824 |
| Ma Songjiang | President |
May 14 '25 |
Sale |
11.30 |
20 |
226 |
2,820,824 |
| Ye Weiguo | Chief Operating Officer |
Apr 01 '25 |
Option Exercise |
0.75 |
50,000 |
37,500 |
700,000 |
5.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):